ReviewInternational journal of molecular sciences2021
Management of Osteoporosis in Men: A Narrative Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis.Journal of bone and mineral metabolism · 2023Pooled it
- Sex differences in the association between bone mineral density and lipid profiles in people with type 2 diabetes in southwest China.Metabolism open · 2026Article
- Osteoporosis Treatment Gap - A Systematic Literature Review.Zdravstveno varstvo · 2026Review
- Sex and age-specific medication interaction in osteoporosis risk.GeroScience · 2026Article
- Denosumab safety in men with osteoporosis: a disproportionality analysis of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- A beneficial effect of a novel DKK1 monoclonal antibody and its sequential alendronate on bone and muscle properties of orchiectomized mice.Journal of orthopaedic translation · 2026Article
- Review
- Association Between Femoral Neck Bone Mineral Density and Osteoporotic Fracture Counts in U.S. Adults: A NHANES 2005-2020 Analysis.Orthopedic reviews · 2026Article
- Linking the relationship between drug-induced osteoporosis and the gut microbiota.Frontiers in endocrinology · 2026Review
- Endocrine-related osteoporosis: the state of the art.Frontiers in endocrinology · 2026Review
- Association Between Arterial Stiffness and Bone Microarchitectural Deterioration in Type 2 Diabetes: A Cross-Sectional Study.Journal of diabetes · 2025Article
- Hip Fractures and Hypogonadism in Young Males: A Missed Opportunity for Secondary Prevention?Cureus · 2025Article
- Association between dietary choline intake and bone mineral density in adolescents: a NHANES-based study.BMC pediatrics · 2025Article
- Role of TyG, TyG-BMI and METS-IR in osteoporosis risk among older men: a retrospective cohort study.Asia Pacific journal of clinical nutrition · 2025Article
- Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder.The Journal of clinical endocrinology and metabolism · 2025Review
- Targeting the PTN/PTPRZ1-ROS Pathway to Promote Bone Regeneration.Biomedicines · 2025Article
- Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Radiofrequency Echographic Multi Spectrometry-A Novel Tool in the Diagnosis of Osteoporosis and Prediction of Fragility Fractures: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Alendronate for Effective Treatment of Male Osteoporosis: An Insight.Current pharmaceutical design · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male osteoporosis is a still largely underdiagnosed pathological condition. As a consequence, bone fragility in men remains undertreated mainly due to the low screening frequency and to controversies in the bone mineral density (BMD) testing standards. Up to the 40% of overall osteoporotic fractures affect men, in spite of the fact that women have a significant higher prevalence of osteoporosis. In addition, in males, hip fractures are associated with increased morbidity and mortality as compared to women. Importantly, male fractures occur about 10 years later in life than women, and, therefore, due to the advanced age, men may have more comorbidities and, consequently, their mortality is about twice the rate in women. Gender differences, which begin during puberty, lead to wider bones in males as compared with females. In men, follicle-stimulating hormones, testosterone, estrogens, and sex hormone-binding levels, together with genetic factors, interact in determining the peak of bone mass, BMD maintenance, and lifetime decrease. As compared with women, men are more frequently affected by secondary osteoporosis. Therefore, in all osteoporotic men, a complete clinical history should be collected and a careful physical examination should be done, in order to find clues of a possible underlying diseases and, ultimately, to guide laboratory testing. Currently, the pharmacological therapy of male osteoporosis includes aminobisphosphonates, denosumab, and teriparatide. Hypogonadal patients may be treated with testosterone replacement therapy. Given that the fractures related to mortality are higher in men than in women, treating male subjects with osteoporosis is of the utmost importance in clinical practice, as it may impact on mortality even more than in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.